Trial Profile
Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections Among Colorectal Surgery Patients (Triple IN Study --Inhibition of Incisional Infections)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Myeloperoxidase (Primary)
- Indications Bacterial infections; Surgical wound infections; Viral infections
- Focus Therapeutic Use
- Acronyms Triple IN
- 02 Oct 2019 According to an Exoxemis Media Release, 250 human subjects in each arm, at 25 U.S. and 5 Israeli sites.
- 02 Oct 2019 Status changed from active, no longer recruiting to completed, according to an Exoxemis Media Release.
- 02 Oct 2019 Results presented in an Exoxemis Media Release.